Reassuringly, recent studies have demonstrated that GLP-1R agonist therapy is not associated with increased risk of serious gastrointestinal adverse events, including ileus, intestinal obstruction, IBD-related hospitalization, corticosteroid use, medication escalation, or IBD-related surgery [131,173,174]. Here, GLP1R is linked to irritable bowel syndrome.